z-logo
open-access-imgOpen Access
Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019
Author(s) -
AnneSophie Bedin,
Alain Makinson,
MarieChristine Picot,
Frank Mennechet,
Fabrice Malergue,
Amandine Pisoni,
Esperance Nyiramigisha,
Lise Montagnier,
Karine Bolloré,
Ségolène Debiesse,
David Morquin,
P Bourgoin,
Nicolas Veyrenche,
Constance Renault,
Vincent Foulongne,
Caroline Bret,
Arnaud Bourdin,
Vincent Le Moing,
Philippe Van de Perre,
Édouard Tuaillon
Publication year - 2020
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa724
Subject(s) - monocyte , medicine , outbreak , coronavirus , biomarker , covid-19 , immunology , disease , triage , cytokine storm , virology , biology , infectious disease (medical specialty) , emergency medicine , biochemistry
We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (monocyte CD169 [mCD169]) in 53 adult patients admitted to the hospital during the coronavirus disease 2019 (COVID-19) outbreak for a suspicion of severe acute respiratory syndrome coronavirus 2 infection. Monocyte CD169 was strongly overexpressed in 30 of 32 (93.7%) confirmed COVID-19 cases, compared with 3 of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. Monocyte CD169 was associated with the plasma interferon-alpha level and thrombocytopenia. Monocyte CD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom